SHR-1501

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameSHR-1501
Drug Alias NameSHR-1501
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionInterleukin-15 receptor subunit alpha stimulants
TargetsInterleukin-15 receptor subunit alpha
Therapy Area/IndicationsUrinary Bladder NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesFudan UniversityShanghai Hengrui Pharmaceutical Co LtdSuzhou Suncadia Biopharmaceuticals Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsUrinary Bladder NeoplasmsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A